Email Us
Call Us
AUSTIN, Texas – January 20, 2011 – Altogen Labs today announced expanded transient and stable transfection services supporting delivery of siRNA, shRNA, microRNA, mRNA, plasmid DNA, proteins, and other nucleic acid-based research materials across more than 100 mammalian cell lines.
Transfection performance is highly dependent on cell type, delivery chemistry, nucleic acid format, culture conditions, cell density, serum concentration, and experimental design. A transfection protocol that performs well in one cell line may produce substantially lower efficiency or greater cytotoxicity in another. These differences are particularly important when working with primary cells, lymphocytes, neurons, stem cell-derived populations, and other cell types that are historically difficult to transfect. For gene silencing, gene expression, reporter assays, pathway analysis, target validation, and functional genomics studies, inadequate delivery efficiency can introduce substantial experimental variability and reduce the ability to distinguish true biological effects from technical limitations. For this reason, Altogen Labs emphasizes cell line-specific optimization rather than relying on a universal transfection protocol. The company’s transfection platform is supported by a broad technology base that includes reagents and protocols optimized for individual cell types. Depending on the cell line and cargo, transfection conditions can be adjusted for reagent concentration, nucleic acid dose, cell density, incubation period, serum conditions, and post-transfection recovery. For siRNA applications, optimized protocols can achieve high levels of intracellular delivery and target knockdown, with efficiencies frequently exceeding 80% in responsive cell systems as measured by quantitative RT-PCR.
Altogen Labs provides transient transfection services for short-term modulation of gene expression, including siRNA-mediated knockdown, microRNA studies, mRNA expression, and plasmid-based overexpression. Stable transfection services are available for projects requiring long-term expression or suppression, clonal selection, reporter cell line generation, or permanent introduction of recombinant DNA constructs. Reverse transfection formats are also supported for screening and higher-throughput applications in which nucleic acids are arrayed before cell seeding. Protocols can be optimized for serum-containing conditions when appropriate, allowing cells to remain in physiologically relevant culture environments while maintaining acceptable transfection efficiency and viability. Transfection outcomes are verified using quantitative molecular and protein-level assays. Gene expression changes can be assessed by qRT-PCR using appropriate normalization controls, while protein expression or knockdown can be evaluated by automated capillary Western analysis or other validated protein detection methods. Cell viability and morphology can also be monitored to distinguish specific gene modulation from nonspecific cytotoxic effects.
For stable cell line development, successfully transfected populations can be subjected to antibiotic selection, enrichment, single-cell cloning, and clone screening. Candidate clones may then be characterized for target expression, knockdown efficiency, protein production, growth characteristics, and stability over multiple passages. The ability to perform transfection optimization, molecular validation, stable cell line generation, and downstream experimental work within the same laboratory provides continuity across research programs. Following validation, engineered cells can be advanced into pathway studies, screening programs, functional assays, or in vivo efficacy studies as appropriate to the project. Altogen Labs supports pharmaceutical, biotechnology, and academic research programs requiring reproducible nucleic acid and protein delivery in biologically relevant cell systems. By tailoring transfection conditions to the specific cell type and experimental objective, the company enables investigators to conduct gene function and target validation studies in the intended biological model rather than relying on a more easily transfected surrogate cell line.
About Altogen Labs
Altogen Labs is a preclinical CRO supporting drug development programs across oncology, pharmacology, toxicology, and translational research. The company has extensive experience with xenograft tumor models for preclinical efficacy studies and in vivo toxicology for safety evaluation, with a strong emphasis on high-quality, reproducible study execution and full client ownership of project-specific intellectual property. Altogen Labs works with pharmaceutical, biotechnology, and academic organizations worldwide to evaluate therapeutic candidates in validated in vivo models and generate data for efficacy, safety, PK/PD, pathology, and IND-supporting studies. The company provides integrated preclinical services from early-stage evaluation through advanced development.
Contact Information:
Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com